This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Buy 5 Dow Stocks to Strengthen Your Portfolio in 2019
by Nalak Das
The blue-chip index has been witnessing extreme volatility over the last three months.
Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019
by Kinjel Shah
J&J's (JNJ) stock has declined more than 14% since Reuters reported that it knew for decades that its baby powders contained asbestos. It is better to avoid the stock and invest in these three big drug stocks instead.
Pfizer/Merck KGaA End Bavencio Ovarian Cancer Phase III Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio. This is the second ovarian cancer study failure in less than two months.
Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug, Xtandi, met the primary endpoint in a late-stage study that can expand the label of the drug to include hormone-sensitive patients.
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations
by Zacks Equity Research
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.
Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review
by Zacks Equity Research
FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.
Dow 30 Stock Roundup: Nike, Walgreens Boots Earnings Impress
by Swarup Gupta
The Dow suffered a particularly tough week, weighed down by a number of concerns.
5 S&P 500 Stocks Stand Tall Despite Index's Loss of 2018 Gains
by Ritujay Ghosh
A few companies have survived the turbulence because of their internal strengths and are poised to perform well in the near term.
Bristol-Myers to Sell French Consumer Health Unit for $1.6B
by Zacks Equity Research
Bristol-Myers (BMY) receives a $1.6 billion offer for its French consumer health unit from Japanese company, Taisho.
AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.
Merck's Keytruda Gets FDA Approval for Rare Skin Cancer
by Zacks Equity Research
Merck (MRK) wins an accelerated approval from the FDA to expand Keytruda's label for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod
by Zacks Equity Research
Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.
Evofem Shares Up as Birth Control Gel Succeeds in Phase III
by Zacks Equity Research
Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birth control vaginal gel.
Merck's Keytruda Gets EU Nod as Adjuvant Therapy for Melanoma
by Zacks Equity Research
Merck (MRK) gains an EU approval for Keytruda as an adjuvant therapy pertaining to adult patients with advanced melanoma.
Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study
by Zacks Equity Research
Eli Lilly's (LLY) Taltz displays superiority over standard of care medicine Humira in a head-to-head study on patients with active psoriatic arthritis.
J&J Okays $5B Stock Buyback Plan, Stock Remains Stressed
by Zacks Equity Research
J&J's (JNJ) board authorizes a $5-billion share repurchase plan. Stock slips 2.9% on Monday, extending a 10% drop on Friday post publication of a controversial Reuters story.
Merck (MRK) Stock Moves -1.63%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $75.23, marking a -1.63% move from the previous day.
Merck to Acquire Europe's Antelliq Group for $2.4 Billion
by Zacks Equity Research
Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.
Incyte (INCY) Collaborates with Innovent for 3 Candidates
by Zacks Equity Research
Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.
Lilly (LLY) to Acquire Pain Candidate From Private Biotech
by Zacks Equity Research
Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.
J&J Dips 10% as Reuters Says Company Knew of Asbestos in Talc
by Zacks Equity Research
A Reuters article says that J&J (JNJ) knew for decades that its baby powders contained asbestos. J&J stock dips 10%.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
by Zacks Equity Research
The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
J&J's Tremfya Beats Novartis' Cosentyx in Head-to-Head Study
by Zacks Equity Research
J&J's (JNJ) psoriasis drug Tremfya proves to be better than Novartis' Cosentyx in phase III head-to-head study for treating adult patients with moderate to severe plaque psoriasis.
Mallinckrodt's Roxicodone Reformulation Gets CRL From FDA
by Zacks Equity Research
Mallinckrodt (MNK) receives complete response letter from the FDA related to its regulatory application seeking approval for abuse-deterrent reformulation of opioid painkiller, Roxicodone.